BLFS
Price
$27.32
Change
-$0.41 (-1.48%)
Updated
Oct 17 closing price
Capitalization
1.31B
19 days until earnings call
Intraday Buy/Sell Signals
RGEN
Price
$152.60
Change
-$1.95 (-1.26%)
Updated
Oct 17 closing price
Capitalization
8.58B
10 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

BLFS vs RGEN

Header iconBLFS vs RGEN Comparison
Open Charts BLFS vs RGENBanner chart's image
BioLife Solutions
Price$27.32
Change-$0.41 (-1.48%)
Volume$264.29K
Capitalization1.31B
Repligen
Price$152.60
Change-$1.95 (-1.26%)
Volume$1.07M
Capitalization8.58B
BLFS vs RGEN Comparison Chart in %
BLFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BLFS vs. RGEN commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLFS is a Hold and RGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (BLFS: $27.32 vs. RGEN: $152.60)
Brand notoriety: BLFS and RGEN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: BLFS: 60% vs. RGEN: 126%
Market capitalization -- BLFS: $1.31B vs. RGEN: $8.58B
BLFS [@Pharmaceuticals: Other] is valued at $1.31B. RGEN’s [@Pharmaceuticals: Other] market capitalization is $8.58B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $159.93B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $10.96B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BLFS’s FA Score shows that 1 FA rating(s) are green whileRGEN’s FA Score has 1 green FA rating(s).

  • BLFS’s FA Score: 1 green, 4 red.
  • RGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, both BLFS and RGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BLFS’s TA Score shows that 6 TA indicator(s) are bullish while RGEN’s TA Score has 6 bullish TA indicator(s).

  • BLFS’s TA Score: 6 bullish, 3 bearish.
  • RGEN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, BLFS is a better buy in the short-term than RGEN.

Price Growth

BLFS (@Pharmaceuticals: Other) experienced а +1.94% price change this week, while RGEN (@Pharmaceuticals: Other) price change was +5.07% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.29%. For the same industry, the average monthly price growth was +0.51%, and the average quarterly price growth was +14.72%.

Reported Earning Dates

BLFS is expected to report earnings on Nov 06, 2025.

RGEN is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.29% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGEN($8.59B) has a higher market cap than BLFS($1.31B). RGEN YTD gains are higher at: 6.016 vs. BLFS (5.239). RGEN has higher annual earnings (EBITDA): 99.5M vs. BLFS (17.4M). RGEN has more cash in the bank: 709M vs. BLFS (81.8M). BLFS has less debt than RGEN: BLFS (23.8M) vs RGEN (686M). RGEN has higher revenues than BLFS: RGEN (674M) vs BLFS (93.5M).
BLFSRGENBLFS / RGEN
Capitalization1.31B8.59B15%
EBITDA17.4M99.5M17%
Gain YTD5.2396.01687%
P/E RatioN/A511.11-
Revenue93.5M674M14%
Total Cash81.8M709M12%
Total Debt23.8M686M3%
FUNDAMENTALS RATINGS
BLFS vs RGEN: Fundamental Ratings
BLFS
RGEN
OUTLOOK RATING
1..100
1216
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
9693
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4242
P/E GROWTH RATING
1..100
122
SEASONALITY SCORE
1..100
3250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGEN's Valuation (95) in the Biotechnology industry is in the same range as BLFS (99) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to BLFS’s over the last 12 months.

RGEN's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as BLFS (96) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to BLFS’s over the last 12 months.

RGEN's SMR Rating (100) in the Biotechnology industry is in the same range as BLFS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to BLFS’s over the last 12 months.

RGEN's Price Growth Rating (42) in the Biotechnology industry is in the same range as BLFS (42) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to BLFS’s over the last 12 months.

RGEN's P/E Growth Rating (2) in the Biotechnology industry is in the same range as BLFS (12) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to BLFS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BLFSRGEN
RSI
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 9 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
77%
Aroon
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
BLFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCEBX11.11N/A
N/A
Goldman Sachs Clean Energy Income A
SUVZX13.50N/A
N/A
PGIM Quant Solutions Large-Cap Val Z
HRSGX12.90N/A
N/A
Harbor Small Cap Growth Admin
AMLPX8.96N/A
N/A
MainGate MLP A
HSWYX22.11N/A
N/A
Hartford Schroders International Stk Y

BLFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with RGEN. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then RGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLFS
1D Price
Change %
BLFS100%
-1.48%
RGEN - BLFS
59%
Loosely correlated
-1.26%
RVTY - BLFS
51%
Loosely correlated
-0.54%
A - BLFS
50%
Loosely correlated
+0.58%
DHR - BLFS
47%
Loosely correlated
-0.88%
ITGR - BLFS
46%
Loosely correlated
+1.66%
More

RGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
-1.26%
DHR - RGEN
67%
Closely correlated
-0.88%
A - RGEN
65%
Loosely correlated
+0.58%
BIO - RGEN
60%
Loosely correlated
-0.76%
MTD - RGEN
59%
Loosely correlated
-0.76%
BLFS - RGEN
59%
Loosely correlated
-1.48%
More